🔗 Share this article

Given that the United States continues making historic changes to its immunization recommendations, a particular individual has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by questioning coronavirus vaccinations in the global health crisis and has focused upon alleged deaths after Covid immunization in her brief position at the Food and Drug Administration.

Scheduled Changes to Childhood Vaccine Schedule

Agency leaders had intended to reveal sweeping changes to the childhood immunization program earlier this month, synchronizing the US with Denmark’s national calendar, sources say – a substantial departure that would place the US out of alignment with a large portion of the world with little proof for benefit. The announcement has been delayed until the next year.

Rather than the top vaccines chief, Høeg is set to present at the meeting. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the center this year.

Consolidating Power at the FDA

The acting appointment may indicate a closer partnership between the drug and biologics centers as Dr. Høeg and Prasad solidify control at the agency – and it points to a renewed priority upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for ending specific childhood immunization guidelines in the US in order to be more in line with the Danish model, a nation with universal health coverage and a citizenry approximately the size of Wisconsin’s.

So far public appearances, she has kept her attention on vaccines – traditionally the responsibility of Prasad, director of the FDA’s vaccine center – instead of medication approval.

Concerns Over Qualifications

The appointee has little discernible experience in medication creation, oversight or administrative roles, which has been customary for past directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for running the drug-regulation department, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in leading a major agency. She has no expertise in industry regulation.”

Past heads of CBER would “grasp legal statutes and the research of drug development”, said Dr. Janet Woodcock. “Clearly, she lacks the type of experience that previous people who led CBER have had.”

This division has an immense workload at the agency, she pointed out.

“Many people just zeroes in on the innovative therapies, but the generic drug division authorizes a multitude of generic medications. There’s a biologic copycat branch, non-prescription drug unit and other areas, and all of those must be supervised,” Dr. Woodcock explained. “The area you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Furthermore, a major management aspect to the job, which manages in excess of 5,000 employees. “It’s a massive leadership role, if you perform it correctly,” the former official said.

Response and Contentious Programs

In response to questions about Høeg’s credentials and whether this selection indicates more teamwork among regulatory chiefs on immunizations, a representative stated that the “inquiries stem from incorrect assumptions”.

“Her experience matches the responsibilities of her role,” the official stated, noting the time Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg inherits the commissioner’s controversial priority voucher program, a contentious expedited medication authorization process that allegedly concerned her preceding directors. “How are these therapies being chosen for this fast-track system? Who is making the calls?” Howard said. “There’s a lot of confidentiality happening at the regulatory body right now.”

Broadly speaking, he remarked, “the FDA appears to be shifting towards more relaxed regulations of pharmaceuticals, with the exception of immunizations.”

Public History on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if problematic, history, critics observe. She authored a analysis using non-validated public submissions to assess the frequency of myocarditis following COVID-19 immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccines are more dangerous than they are.

Among her “policy goals” for the new federal leadership featured changing regulations for novel immunizations and halting “optional” vaccines, she said after the election on a podcast. At the FDA, Høeg has according to sources suggested excluding teenage boys from receiving Covid vaccinations.

“She is an thorough dogmatist who starts off with her preconceived notions and tailors the evidence to fit the evidence in a extremely disingenuous, fraudulent way,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg aligned with other contrarians, {like|